Marina Posts Drop in Q2 Losses | GenomeWeb

Marina Posts Drop in Q2 Losses

Premium

Marina Biotech, formerly MDRNA, reported this month a drop in second-quarter losses amid a 12 percent declined in expenses.

For the three-month period ended June 30, Marina's net loss fell to $4.1 million, or $0.34 per share, from a year-ago loss of $7.5 million, or $0.84 per share.

Revenues in the quarter slipped to $200,000 from $300,000, but this decrease was more than offset by a dip in research and development spending to $7.4 million from $8.5 million. Selling, general, and administrative costs, however, rose 10 percent to $4.8 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.